ArticleJournal of oncology2022
Zinc Oxide Nanoparticle Inhibits Tumorigenesis of Renal Cell Carcinoma by Modulating Lipid Metabolism Targeting miR-454-3p to Repressing Metabolism Enzyme ACSL4.
Article in Journal of oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed, 15 citations in OpenAlex.
- Smart Colloidal Systems as Drug Delivery and Therapeutic Modulation Platforms for Renal Cell Carcinoma.International journal of nanomedicine · 2026Review
- Targeting miRNAs in renal cell carcinoma: emerging therapeutic strategies.International journal of clinical oncology · 2025Review
- Cancer-associated fibroblast-secreted exosomal miR-454-3p inhibits lipid metabolism and ferroptosis in breast cancer by targeting ACSL4.Naunyn-Schmiedeberg's archives of pharmacology · 2025Article
- Review
- Targeting the tumor microenvironment with biomaterials for enhanced immunotherapeutic efficacy.Journal of nanobiotechnology · 2024Review
- Effects of zinc in podocytes and cortical collecting duct in vitro and Dahl salt-sensitive rats in vivo.The Journal of biological chemistry · 2024Article
- Clinical insights into nanomedicine and biosafety: advanced therapeutic approaches for common urological cancers.Frontiers in oncology · 2024Review
- Detection of Ferroptosis by Immunohistochemistry and Immunofluorescence.Methods in molecular biology (Clifton, N.J.) · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Renal cell carcinoma (RCC) affects the life quality of patients with advanced diseases despite good prognosis and exhibits abnormal lipid metabolism. Zinc oxide nanoparticles (ZONs) are metal oxide nanoparticles that are regarded as promising therapeutic candidate for multiple diseases. This study was for exploring the function of ZONs in RCC. Methods: We established Results: ZONs suppressed the proliferation and viability of RCC cells both Conclusion: ZONs treatment notably impeded proliferation, lipid accumulation, and oxidation in RCC cells, through upregulating miR-454-3p to suppression the function of ACSL4. Our data suggested that ZONs are promising and effective agent for RCC treatment.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.